Bulletin
Investor Alert

London Markets Close in:

Nov. 26, 2021, 12:44 p.m. EST

Immuno-Oncology Treatment Market Scope | Business Research by Leading Countries, Growth Developments and Opportunities, Global Share and Trends, Company Profiles Forecast to 2027

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Amgen Inc. (AMGN)
  • X
    Pfizer Inc. (PFE)

or Cancel Already have a watchlist? Log In

Nov 26, 2021 (AmericaNewsHour) -- Research Nester released a report titled "Immuno-Oncology Treatment Market: Global Demand Analysis & Opportunity Outlook 2027" which delivers detailed overview of the global immuno-oncology treatment market in terms of market segmentation by product, by administration, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter's five force model.

The  market for immune-oncology treatment  is projected to grow by a CAGR of 12.68% during the forecast period, i.e., 2020-2027. Moreover, the market is anticipated to attain a value of USD 157,230.48 million by the end of the year 2027. Immuno-oncology treatment is a cancer therapy that involves targeting cancerous cells by stimulating the body's immune system. The market is segmented by product, by administration, by end user and by region. On the basis of administration, the market is bifurcated into standalone therapy and combination therapy, out of which, the combination therapy segment is estimated to hold the largest portion in the market as a result of growing number of approved treatments and higher effectiveness of the therapy.

Based on region, the market is segmented into North America, Latin America, Europe, Asia-Pacific and Middle East and Africa, out of which, the largest share is estimated to be held by the market in North America over the forecast period. The rising investments by various government and private institutions in the healthcare industry for the maintenance of high quality healthcare services and products is anticipated to be the major factor contributing towards the growth of the market in this region.

Download Sample of This Strategic Report:  https://www.researchnester.com/sample-request-2103

Growing Number Of Cancer Patients In Hospitals To Support The Market Growth

According to the World Health Organization, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. The increasing number of patients in hospitals as compared to other smaller healthcare settings is anticipated to be a significant growth driving factor for the immune-oncology market. Moreover, the rising cases of cancer across the globe is another factor estimated to result in the market growth in the upcoming years. However, the limited access to healthcare, especially among the cancer patients residing in low- and middle-income countries, is estimated to become a growth barrier for the market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global immuno-oncology treatment market which includes company profiling of F. Hoffmann-La Roche Ltd (swx:ROG), Merck & Company, Inc. /zigman2/quotes/209956077/composite MRK +0.07% , AstraZeneca Plc. (lon:AZN), Novartis (swx:NOVN), Amgen Inc. /zigman2/quotes/209157011/composite AMGN +1.95% , Pfizer Inc. /zigman2/quotes/202877789/composite PFE -1.06% , Bristol-Myers Squibb Company /zigman2/quotes/202559280/composite BMY +0.51% , Eli Lilly and Company /zigman2/quotes/200106384/composite LLY -2.22% , Janssen and GlaxoSmithKline plc. (lon:GSK).

Request For Full Report @  https://www.researchnester.com/sample-request-2103

The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global immuno-oncology treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

About Research Nester

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

The post Immuno-Oncology Treatment Market Scope | Business Research by Leading Countries, Growth Developments and Opportunities, Global Share and Trends, Company Profiles Forecast to 2027 appeared first on America News Hour .

COMTEX_397782742/2606/2021-11-26T12:43:37

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 81.38
+0.06 +0.07%
Volume: 0.00
Jan. 14, 2022 4:02p
P/E Ratio
28.73
Dividend Yield
3.39%
Market Cap
$205.56 billion
Rev. per Employee
$660,851
loading...
/zigman2/quotes/209157011/composite
US : U.S.: Nasdaq
$ 235.36
+4.51 +1.95%
Volume: 0.00
Jan. 14, 2022 4:00p
P/E Ratio
24.25
Dividend Yield
3.30%
Market Cap
$132.57 billion
Rev. per Employee
$1.06M
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 54.95
-0.59 -1.06%
Volume: 0.00
Jan. 14, 2022 4:02p
P/E Ratio
16.31
Dividend Yield
2.91%
Market Cap
$308.43 billion
Rev. per Employee
$883,274
loading...
/zigman2/quotes/202559280/composite
US : U.S.: NYSE
$ 64.93
+0.33 +0.51%
Volume: 0.00
Jan. 14, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
3.33%
Market Cap
$144.12 billion
Rev. per Employee
$1.50M
loading...
/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 244.12
-5.55 -2.22%
Volume: 0.00
Jan. 14, 2022 4:02p
P/E Ratio
37.27
Dividend Yield
1.61%
Market Cap
$233.52 billion
Rev. per Employee
$793,100
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.